NCT01031277

Brief Summary

The purpose of the study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country, to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III in the following sub-populations:

  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome (according to NCEP III definition). And to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in the following sub-populations:
  • Primary/secondary prevention patients.
  • Patients with metabolic syndrome.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2009

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 11, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

December 14, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2010

Completed
Last Updated

May 25, 2011

Status Verified

May 1, 2011

Enrollment Period

8 months

First QC Date

December 11, 2009

Last Update Submit

May 24, 2011

Conditions

Hypercholesterolemia

Keywords

HypercholesterolemiaUpdate NCEP ATP111Survey

Outcome Measures

Primary Outcomes (1)

  • To establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the NCEP ATP III/updated 2004 NCEP ATP III guidelines, overall and by country.

    6 months- One visit only, no follow up visits.

Secondary Outcomes (3)

  • Proportion patients on lipid-lowering drugs (LLD) reaching the LDL-C goals according to the NCEP ATP III/ updated 2004 NCEP ATP III in subgroups: Primary/secondary prevention patients; Patients with metabolic syndrome ( NCEP III).

    6 months- One visit only, no follow up visits.

  • Proportion patients on LLD reaching the LDL-C goals according to the Third Joint European Task Force guidelines/national guidelines, in the survey population and in sub-populations: Primary/secondary prevention patients; Patients with metabolic syndrome.

    6 months- One visit only, no follow up visits.

  • To identify determinants (e.g. patient and physician characteristics, country-specific guidelines or recommendations) for undertreatment of hypercholesterolemia.

    6 months- One visit only, no follow up visits.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Inhabitants of Gulf States visiting their cardiologist for regular follow-up of their hypercholesterolaemia treatment

You may qualify if:

  • Race
  • On lipid-lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.
  • Subject must sign informed consent

You may not qualify if:

  • Subjects who are unwilling or unable to provide informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Research Site

Abu Dhabi, United Arab Emirates

Location

Related Publications (1)

  • Shehab A, Al-Rasadi K, Arafah M, Al-Hinai AT, Al Mahmeed W, Bhagavathula AS, Al Tamimi O, Al Herz S, Al Anazi F, Al Nemer K, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Al Jassim O, Al Hallaq O, Baslaib FOAS, Alawadhi M, Amin H, Al-Hashmi K, Oulhaj A. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings. Curr Vasc Pharmacol. 2018;16(4):368-375. doi: 10.2174/1570161115666170705153815.

    PMID: 28677510DERIVED

Biospecimen

Retention: NONE RETAINED

Whole blood

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Prof. Wael Al Mahmeed

    Shaikh Khalifa Medical City

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

December 11, 2009

First Posted

December 14, 2009

Study Start

November 1, 2009

Primary Completion

July 1, 2010

Study Completion

July 1, 2010

Last Updated

May 25, 2011

Record last verified: 2011-05

Locations

AE(1)